HCRT and non-functioning pituitary adenoma: Considering the comparison between groups of neurocognitive disorders, mAD patients presented lower CSF orexin-A levels than msAD (p < 0.001), bv-FTD (p = 0.04), NFPA (p < 0.001), or iNPH (p < 0.001) patients.